Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroblastoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Ganglioneuroblastoma 3Burkitt Lymphoma 3Urinary Bladder Neoplasms 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Breast Neoplasms 2Teratoma 1Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma, Alveolar 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Radiotherapy 3Fluorouracil 3Cisplatin 3Nivolumab 2Mitomycin 2X-Rays 1Watchful Waiting 1Taxes 1Specimen Handling 1Sigmoidoscopy 1Radiation 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Immune Checkpoint Inhibitors 1Colonoscopy 1Chemoradiotherapy 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anal Canal Carcinoma × Biopsy × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡